

Rev Soc Esp Dolor  
2013; 20(1): 40

*Sr Director:*

Le adjunto el boletín de la IASP donde se muestran los cambios en sus comités y que afectan a nuestro país, ya que se han incluido a los Dres. J. A. López López, neurocirujano de la Unidad del dolor del Hospital Universitario Puerta del Mar de Cádiz, como secretario del Comité Ejecutivo y al Dr. E. Latorre como miembro del Newsletter committee. Enhorabuena a ambos.

L. M. Torres

*Director de la RESED*



### **SIG Leadership**

#### **Executive Committee**

Chair: H. Knotkova, USA

Chair-Elect: V. Tronnier, Germany

Treasurer: V. Stock, USA

Secretary: J. Lopez, Spain

Timely topics in pain research and treatment have been selected for publication, but the information provided and opinions expressed have not involved any verification of the findings, conclusions, and opinions by the International Association for the Study of Pain (IASP)® or the SIG on Neuromodulation. The opinions expressed in this newsletter do not necessarily reflect those of the Association, the SIG, or the Officers and Councilors of either IASP or the SIG on Neuromodulation. No responsibility is assumed by the Association or the SIG for any injury and/or damage to persons or property as a matter of products liability, negligence, or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of the rapid advances of medical

science, the publisher recommends independent verification of diagnoses and drug dosage.

### **Welcome from the Chair**

Dear Members of SIGN

It is great news that after several months of preparations and “in formation” status, SIGN has been unanimously approved by the IASP General Assembly as a functional SIG. During the preparatory period, the SIGN Bylaws were developed and approved by SIG members in March 2012, committees of SIGN were formed, and SIGN held its first business meeting at the 14th World Congress on Pain in Milan, Italy.

SIGN was established to promote interdisciplinary collaboration among scientists, clinicians and other professionals in research and clinical application of neuromodulatory treatment strategies, to facilitate inter-professional education and training in the field of neuromodulation, to provide a platform and forum for ongoing professional discourse in order to address emerging issues, and to navigate the development of evidence-based practices and policies. To fulfill SIGN’s mission, we will implement various activities and will delineate SIGN work in goals set for two-year increments, and action plans for each year.

Based on your input over the past months, SIGN committees finalized goals for the upcoming two-year period. Activities related to each specific goal will be carried out by a working group of members interested in the goal, and navigated by a designated SIGN committee. We are looking forward to working together with you! In this exciting field of expertise, SIGN gives us a great opportunity to facilitate research and clinical applications of neuromodulation in pain and symptom management.



**Fig. 1.**

Helena Knotkova